WHITEHAWK THERAPEUTICS, INC. Operating Expenses
WHITEHAWK THERAPEUTICS, INC. (WHWK) reported Operating Expenses of $112.34 million for the 12-month period ending 2021-12-31, per its 10-K filed 2022-03-17.
Discontinued › Expense Statement › Operating Expenses
us-gaap:OperatingExpenses · last filed 2022-03-17
- WHITEHAWK THERAPEUTICS, INC. operating expenses for the quarter ending 2021-12-31 was $16.95M, a 194.95% increase year-over-year.
- WHITEHAWK THERAPEUTICS, INC. operating expenses for the quarter ending 2021-09-30 was $87.31M, a 2916.97% increase year-over-year.
- WHITEHAWK THERAPEUTICS, INC. operating expenses for the quarter ending 2021-06-30 was $4.77M, a 16.93% decline year-over-year.
- WHITEHAWK THERAPEUTICS, INC. operating expenses for the quarter ending 2021-03-31 was $5.60M, a 36.16% increase year-over-year.
- WHITEHAWK THERAPEUTICS, INC. operating expenses for fiscal 2021 was $112.34M, a 555.83% increase from fiscal 2020.
- WHITEHAWK THERAPEUTICS, INC. operating expenses for fiscal 2020 was $17.13M, a 29.93% decline from fiscal 2019.
- WHITEHAWK THERAPEUTICS, INC. operating expenses for fiscal 2019 was $24.44M, a 22.00% decline from fiscal 2018.
- WHITEHAWK THERAPEUTICS, INC. operating expenses for fiscal 2018 was $31.34M, a 46.52% increase from fiscal 2017.
| Period end | Operating Expenses 3 month | Operating Expenses 3 month as first filed | Operating Expenses 6 month | Operating Expenses 9 month | Operating Expenses 9 month as first filed | Operating Expenses 12 month | Operating Expenses 12 month as first filed |
|---|---|---|---|---|---|---|---|
| 2021-12-31 | $16.95M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-17 | $104.26M derived: sum of 2 quarters · filed 2022-03-17 | $109.03M derived: sum of 3 quarters · filed 2022-03-17 | $112.34M 10-K · filed 2022-03-17 | |||
| 2021-09-30 | $87.31M 10-Q · filed 2021-11-10 | $92.08M derived: sum of 2 quarters · filed 2021-11-10 | $95.39M 10-Q · filed 2021-11-10 | $103.43M derived: sum of 4 quarters · filed 2022-03-17 | |||
| 2021-06-30 | $4.77M 10-Q · filed 2021-08-11 | $10.37M 10-Q · filed 2021-08-11 | $16.12M derived: sum of 3 quarters · filed 2022-03-17 | $19.01M derived: sum of 4 quarters · filed 2022-03-17 | |||
| 2021-03-31 | $5.60M 10-Q · filed 2021-05-17 | $11.35M derived: sum of 2 quarters · filed 2022-03-17 | $14.24M derived: sum of 3 quarters · filed 2022-03-17 | $19.99M derived: sum of 4 quarters · filed 2022-03-17 | |||
| 2020-12-31 | $5.75M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-17 | $8.64M derived: sum of 2 quarters · filed 2022-03-17 | $14.38M derived: sum of 3 quarters · filed 2022-03-17 | $17.13M 10-K · filed 2022-03-17 | $21.36M 10-K · filed 2021-03-11 | ||
| 2020-09-30 | $2.89M 10-Q · filed 2021-11-10 | $5.86M 10-Q · filed 2020-11-10 | $8.64M derived: sum of 2 quarters · filed 2021-11-10 | $11.38M 10-Q · filed 2021-11-10 | $15.72M 10-Q · filed 2020-11-10 | $17.41M derived: sum of 4 quarters · filed 2021-11-10 | |
| 2020-06-30 | $5.74M 10-Q · filed 2021-08-11 | $9.86M 10-Q · filed 2021-08-11 | $14.52M derived: sum of 3 quarters · filed 2021-08-11 | $19.48M derived: sum of 4 quarters · filed 2021-08-11 | |||
| 2020-03-31 | $4.11M 10-Q · filed 2021-05-17 | $8.77M derived: sum of 2 quarters · filed 2021-05-17 | $13.74M derived: sum of 3 quarters · filed 2021-05-17 | $19.72M derived: sum of 4 quarters · filed 2021-05-17 | |||
| 2019-12-31 | $4.66M 10-K · filed 2020-03-16 | $9.62M derived: sum of 2 quarters · filed 2020-11-10 | $15.60M derived: sum of 3 quarters · filed 2020-11-10 | $24.44M 10-K · filed 2021-03-11 | |||
| 2019-09-30 | $4.97M 10-Q · filed 2020-11-10 | $10.95M derived: sum of 2 quarters · filed 2020-11-10 | $19.79M 10-Q · filed 2020-11-10 | $28.66M derived: sum of 4 quarters · filed 2020-11-10 | |||
| 2019-06-30 | $5.98M 10-Q · filed 2020-08-12 | $14.82M 10-Q · filed 2020-08-12 | $23.69M derived: sum of 3 quarters · filed 2020-08-12 | $31.31M derived: sum of 4 quarters · filed 2020-08-12 | |||
| 2019-03-31 | $8.84M 10-Q · filed 2020-05-07 | $17.71M derived: sum of 2 quarters · filed 2020-05-07 | $25.33M derived: sum of 3 quarters · filed 2020-05-07 | $32.70M derived: sum of 4 quarters · filed 2020-05-07 | |||
| 2018-12-31 | $8.87M 10-K · filed 2020-03-16 | $16.49M derived: sum of 2 quarters · filed 2020-03-16 | $23.86M derived: sum of 3 quarters · filed 2020-03-16 | $31.34M 10-K · filed 2020-03-16 | |||
| 2018-09-30 | $7.62M 10-K · filed 2020-03-16 | $14.99M derived: sum of 2 quarters · filed 2020-03-16 | $22.47M 10-Q · filed 2019-11-07 | $28.76M derived: sum of 4 quarters · filed 2020-03-16 | |||
| 2018-06-30 | $7.37M 10-K · filed 2020-03-16 | $14.85M 10-Q · filed 2019-08-08 | $21.14M derived: sum of 3 quarters · filed 2020-03-16 | $25.89M derived: sum of 4 quarters · filed 2020-03-16 | |||
| 2018-03-31 | $7.48M 10-K · filed 2020-03-16 | $13.77M derived: sum of 2 quarters · filed 2020-03-16 | $18.52M derived: sum of 3 quarters · filed 2020-03-16 | $24.11M derived: sum of 4 quarters · filed 2020-03-16 | |||
| 2017-12-31 | $6.29M 10-K · filed 2019-03-07 | $11.05M derived: sum of 2 quarters · filed 2019-03-07 | $16.63M derived: sum of 3 quarters · filed 2019-03-07 | $21.39M 10-K · filed 2019-03-07 | |||
| 2017-09-30 | $4.76M 10-K · filed 2019-03-07 | $10.34M derived: sum of 2 quarters · filed 2019-03-07 | $15.10M 10-Q · filed 2018-11-07 | $18.41M derived: sum of 4 quarters · filed 2019-03-07 | |||
| 2017-06-30 | $5.58M 10-K · filed 2019-03-07 | $10.34M 10-Q · filed 2018-08-14 | $13.65M derived: sum of 3 quarters · filed 2019-03-07 | $18.39M derived: sum of 4 quarters · filed 2019-03-07 | |||
| 2017-03-31 | $4.76M 10-K · filed 2019-03-07 | $8.06M derived: sum of 2 quarters · filed 2019-03-07 | $12.81M derived: sum of 3 quarters · filed 2019-03-07 | $17.19M derived: sum of 4 quarters · filed 2019-03-07 | |||
| 2016-12-31 | $3.31M 10-K · filed 2018-03-15 | $8.05M derived: sum of 2 quarters · filed 2018-03-15 | $12.43M derived: sum of 3 quarters · filed 2018-03-15 | $16.63M 10-K · filed 2018-03-15 | |||
| 2016-09-30 | $4.75M 10-K · filed 2018-03-15 | $9.12M derived: sum of 2 quarters · filed 2018-03-15 | $13.33M 10-Q · filed 2017-11-13 | ||||
| 2016-06-30 | $4.38M 10-K · filed 2018-03-15 | $8.58M 10-Q · filed 2017-08-10 | |||||
| 2016-03-31 | $4.21M 10-K · filed 2018-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Eledon Pharmaceuticals, Inc. (ELDN) | United States | $0.219B | -3.23 |
| NATURES SUNSHINE PRODUCTS INC (NATR) | United States | $0.228B | 20.51 |
| Foghorn Therapeutics Inc. (FHTX) | United States | $0.213B | -4.43 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| Nkarta, Inc. (NKTX) | United States | $0.205B | -1.73 |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |